These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22263803)

  • 1. NGR-based strategies for targeting delivery of chemotherapeutics to tumor vasculature.
    Zou M; Zhang L; Xie Y; Xu W
    Anticancer Agents Med Chem; 2012 Mar; 12(3):239-46. PubMed ID: 22263803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile.
    Dreischalück J; Schwöppe C; Spieker T; Kessler T; Tiemann K; Liersch R; Schliemann C; Kreuter M; Kolkmeyer A; Hintelmann H; Mesters RM; Berdel WE
    Int J Oncol; 2010 Dec; 37(6):1389-97. PubMed ID: 21042706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example.
    Corti A; Curnis F; Rossoni G; Marcucci F; Gregorc V
    BioDrugs; 2013 Dec; 27(6):591-603. PubMed ID: 23743670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor vasculature targeting through NGR peptide-based drug delivery systems.
    Corti A; Curnis F
    Curr Pharm Biotechnol; 2011 Aug; 12(8):1128-34. PubMed ID: 21470145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo NIRF imaging-guided delivery of a novel NGR-VEGI fusion protein for targeting tumor vasculature.
    Ma W; Li G; Wang J; Yang W; Zhang Y; Conti PS; Chen K
    Amino Acids; 2014 Dec; 46(12):2721-32. PubMed ID: 25182731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of NGR-based anti-cancer agents for targeted therapeutics and imaging.
    Wang RE; Niu Y; Wu H; Hu Y; Cai J
    Anticancer Agents Med Chem; 2012 Jan; 12(1):76-86. PubMed ID: 22023047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.
    Bieker R; Kessler T; Schwöppe C; Padró T; Persigehl T; Bremer C; Dreischalück J; Kolkmeyer A; Heindel W; Mesters RM; Berdel WE
    Blood; 2009 May; 113(20):5019-27. PubMed ID: 19179306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of cyclic NGR tumor neovasculature-homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth.
    Jiang W; Jin G; Ma D; Wang F; Fu T; Chen X; Chen X; Jia K; Marikar FM; Hua Z
    PLoS One; 2012; 7(5):e37132. PubMed ID: 22590653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.
    Curnis F; Arrigoni G; Sacchi A; Fischetti L; Arap W; Pasqualini R; Corti A
    Cancer Res; 2002 Feb; 62(3):867-74. PubMed ID: 11830545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo tumor targeting by a NGR-decorated micelle of a recombinant diblock copolypeptide.
    Simnick AJ; Amiram M; Liu W; Hanna G; Dewhirst MW; Kontos CD; Chilkoti A
    J Control Release; 2011 Oct; 155(2):144-51. PubMed ID: 21763734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of an aminopeptidase N-binding sequence to human endostatin improves inhibition of ovarian carcinoma growth.
    Yokoyama Y; Ramakrishnan S
    Cancer; 2005 Jul; 104(2):321-31. PubMed ID: 15952188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neovasculature homing motif NGR: more than meets the eye.
    Corti A; Curnis F; Arap W; Pasqualini R
    Blood; 2008 Oct; 112(7):2628-35. PubMed ID: 18574027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Growth Inhibition via Occlusion of Tumor Vasculature Induced by N-Terminally PEGylated Retargeted Tissue Factor tTF-NGR.
    Brand C; Fröhlich M; Ring J; Schliemann C; Kessler T; Mantke V; König S; Lücke M; Mesters RM; Berdel WE; Schwöppe C
    Mol Pharm; 2015 Oct; 12(10):3749-58. PubMed ID: 26310827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research Progress of Radiolabeled Asn-Gly-Arg (NGR) Peptides for Imaging and Therapy.
    Zhu L; Ding Z; Li X; Wei H; Chen Y
    Mol Imaging; 2020; 19():1536012120934957. PubMed ID: 32862776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature.
    Mukhopadhyay S; Barnés CM; Haskel A; Short SM; Barnes KR; Lippard SJ
    Bioconjug Chem; 2008 Jan; 19(1):39-49. PubMed ID: 17845003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of Action of the Tumor Vessel Targeting Agent NGR-hTNF: Role of Both NGR Peptide and hTNF in Cell Binding and Signaling.
    Valentinis B; Porcellini S; Asperti C; Cota M; Zhou D; Di Matteo P; Garau G; Zucchelli C; Avanzi NR; Rizzardi GP; Degano M; Musco G; Traversari C
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31547231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis.
    Pasqualini R; Koivunen E; Kain R; Lahdenranta J; Sakamoto M; Stryhn A; Ashmun RA; Shapiro LH; Arap W; Ruoslahti E
    Cancer Res; 2000 Feb; 60(3):722-7. PubMed ID: 10676659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
    Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching.
    Curnis F; Cattaneo A; Longhi R; Sacchi A; Gasparri AM; Pastorino F; Di Matteo P; Traversari C; Bachi A; Ponzoni M; Rizzardi GP; Corti A
    J Biol Chem; 2010 Mar; 285(12):9114-23. PubMed ID: 20064928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells.
    Di Matteo P; Hackl C; Jedeszko C; Valentinis B; Bordignon C; Traversari C; Kerbel RS; Rizzardi GP
    Br J Cancer; 2013 Jul; 109(2):360-9. PubMed ID: 23828516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.